H.R. 8553: Precision Oncology Program for Cancer of the Prostate Authorization Act of 2026

This bill, known as the Precision Oncology Program for Cancer of the Prostate Authorization Act of 2026, aims to establish a specialized program within the Department of Veterans Affairs (VA) to improve the diagnosis and treatment of prostate cancer among veterans. Here are the main features and sections of the bill:

Establishment of the Precision Oncology Program

The bill mandates the Secretary of Veterans Affairs to create a precision oncology program specifically targeted at prostate cancer. This includes:

• Designating certain medical facilities as "Centers of Excellence" that will provide advanced care for prostate cancer.
• Ensuring that veterans diagnosed with prostate cancer can enroll in medical services through this new program.

Requirements for Centers of Excellence

Centers designated under this program must:

• Implement a program for genetic sequencing for veterans with advanced prostate cancer.
• Participate in the national Telemedicine Tumor Board and track genetic mutations in a prostate cancer registry.
• Facilitate travel support for veterans with certain genetic mutations to encourage their participation in studies.
• Engage in conducting biomarker-specific clinical trials and participate in industry-sponsored precision oncology studies.

Staffing and Resources

Each Center of Excellence must include a multidisciplinary team composed of:

• A medical oncologist
• An interventional radiologist
• A urologist
• A radiation oncologist
• A pathologist
• Two research staff members

The Secretary is required to ensure the presence of a minimum number of Centers of Excellence across the network, specifically at least 21 facilities at all times.

Performance Reviews and Reporting

Performance evaluations will be conducted on the Centers of Excellence at least every five years. The Secretary will be responsible for assessing whether each Center continues to meet the necessary criteria for designation. Additionally, an annual report will be submitted, detailing:

• Funding levels for each center
• Participation rates of veterans in the program
• Outcomes related to prostate cancer research and treatment

Implementation and Funding

The bill authorizes an appropriation of $15.5 million for each fiscal year from 2027 to 2029 to implement the program. The VA is tasked with establishing the program within 180 days post-enactment and submitting an implementation plan that outlines staffing requirements, funding, and development plans for the sequencing platform and cancer registry.

Long-Term Commitment

The designated Centers of Excellence will retain their designation for a minimum of five years, ensuring stability in prostate cancer care and research access to veterans and maintaining funding at levels that existed as of January 1, 2023, until January 1, 2030.

Relevant Companies

• AMGN (Amgen Inc.): As a biotech company involved in oncology drug development, changes in VA cancer treatment approaches may affect research partnerships and sales of relevant therapies.
• NVS (Novartis): This pharmaceutical company develops cancer treatments and may see changes in demand based on new therapies introduced through the VA’s precision oncology program.
• EXAS (Exact Sciences): Specializes in cancer screening and detection. This bill could influence the types of tests and procedures adopted within the Veterans Health Administration.